Diamyd Medical Ab Stock Current Valuation
| DMN Stock | EUR 1.07 0.01 0.94% |
Valuation analysis of Diamyd Medical AB helps investors to measure Diamyd Medical's intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns.
Overvalued
Today
Please note that Diamyd Medical's price fluctuation is dangerous at this time. Calculation of the real value of Diamyd Medical AB is based on 3 months time horizon. Increasing Diamyd Medical's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Diamyd stock is determined by what a typical buyer is willing to pay for full or partial control of Diamyd Medical AB. Since Diamyd Medical is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Diamyd Stock. However, Diamyd Medical's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 1.07 | Real 0.92 | Hype 1.07 |
The real value of Diamyd Stock, also known as its intrinsic value, is the underlying worth of Diamyd Medical AB Company, which is reflected in its stock price. It is based on Diamyd Medical's financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Diamyd Medical's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of Diamyd Medical AB helps investors to forecast how Diamyd stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Diamyd Medical more accurately as focusing exclusively on Diamyd Medical's fundamentals will not take into account other important factors: Diamyd Medical AB Company Current Valuation Analysis
Diamyd Medical's Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Diamyd Medical Current Valuation | 96.81 M |
Most of Diamyd Medical's fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Diamyd Medical AB is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Diamyd Medical AB has a Current Valuation of 96.81 M. This is 99.33% lower than that of the Healthcare sector and 97.92% lower than that of the Biotechnology industry. The current valuation for all Germany stocks is 99.42% higher than that of the company.
Diamyd Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Diamyd Medical's direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Diamyd Medical could also be used in its relative valuation, which is a method of valuing Diamyd Medical by comparing valuation metrics of similar companies.Diamyd Medical is currently under evaluation in current valuation category among its peers.
Diamyd Fundamentals
| Return On Equity | -0.42 | |||
| Return On Asset | -0.25 | |||
| Current Valuation | 96.81 M | |||
| Shares Outstanding | 76.93 M | |||
| Shares Owned By Insiders | 35.22 % | |||
| Shares Owned By Institutions | 0.26 % | |||
| Price To Book | 5.52 X | |||
| Price To Sales | 2,594 X | |||
| Revenue | 454 K | |||
| Gross Profit | (3.95 M) | |||
| EBITDA | (98.88 M) | |||
| Net Income | (103.52 M) | |||
| Current Ratio | 5.83 X | |||
| Book Value Per Share | 0.09 X | |||
| Cash Flow From Operations | (93.22 M) | |||
| Earnings Per Share | (0.11) X | |||
| Target Price | 19.0 | |||
| Number Of Employees | 20 | |||
| Beta | 1.91 | |||
| Market Capitalization | 99.6 M | |||
| Total Asset | 236.52 M | |||
| Net Asset | 236.52 M |
About Diamyd Medical Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Diamyd Medical AB's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Diamyd Medical using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Diamyd Medical AB based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Other Information on Investing in Diamyd Stock
Diamyd Medical financial ratios help investors to determine whether Diamyd Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Diamyd with respect to the benefits of owning Diamyd Medical security.